Increased Cytoplasmic CD138 Expression Is Associated with Aggressive Characteristics in Prostate Cancer and Is an Independent Predictor for Biochemical Recurrence

Table 3

Membranous CD138 staining and prostate cancer phenotype.

Parameter	evaluable	Negative (%)	Weak (%)	Moderate (%)	Strong (%)	value
All cancers	12851	80.4	9.0	8.3	2.2
Tumor stage						<0.0001
pT2	8124	81.5	8.1	8.2	2.3
pT3a	2967	78.9	10.2	8.7	2.2
pT3b-pT4	1709	78.4	11.7	8.4	1.5
Gleason grade						<0.0001
≤3+3	2176	84.5	7.4	6.7	1.5
3+4	7016	79.0	9.2	9.2	2.5
3+4 Tert.5	632	82.6	8.2	7.9	1.3
4+3	1269	80.5	9.5	7.9	2.1
4+3 Tert.5	952	80.1	10.1	7.9	1.9
≥4+4	685	82.0	10.4	6.0	1.6
Quantitative Gleason grade
≤3+3	2176	84.5	7.4	6.7	1.5	<0.0001
	1683	80.7	8.2	8.3	2.8
3+4 6-10%	1786	79.3	9.1	8.8	2.8
3+4 11-20%	1577	78.3	10.4	9.6	1.7
3+4 21-30%	806	77.4	7.6	10.9	4.1
3+4 31-49%	614	79.5	8.1	10.3	2.1
3+4 Tert.5	632	82.6	8.2	7.9	1.3
4+3 50-60%	522	80.5	9.8	8.2	1.5
4+3 Tert.5	952	80.1	10.1	7.9	1.9
4+3 61-<100%	564	82.6	7.8	7.1	2.5
≥4+4	600	81.7	10.3	6.3	1.7
Lymph node metastasis						0.2053
N0	7842	80.1	9.5	8.3	2.1
N+	935	79.1	11.2	8.2	1.4
Preoperative PSA level (ng/ml)						<0.0001
<4	1457	79.1	9.6	9.3	2.0
4-10	7580	79.6	9.1	8.9	2.5
10-20	2761	82.2	8.6	7.4	1.8
>20	976	84.7	9.0	5.2	1.0
Surgical margin						0.3745
Negative	10114	80.2	9.1	8.4	2.3
Positive	2691	81.4	8.7	8.1	1.8